Charles Ryhee
Stock Analyst at TD Cowen
(1.70)
# 3,161
Out of 4,749 analysts
25
Total ratings
42.86%
Success rate
-1.92%
Average return
Main Sectors:
Stocks Rated by Charles Ryhee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CVS CVS Health | Maintains: Buy | $73 → $80 | $56.48 | +41.64% | 5 | Nov 25, 2024 | |
| WBA Walgreens Boots Alliance | Maintains: Buy | $16 → $14 | $10.28 | +36.19% | 6 | Oct 22, 2024 | |
| MCK McKesson | Maintains: Buy | $563 → $652 | $594.75 | +9.63% | 4 | May 8, 2024 | |
| CVX Chevron | Maintains: Outperform | $185 → $170 | $149.19 | +13.95% | 3 | Feb 24, 2023 | |
| EVH Evolent Health | Maintains: Outperform | $57 → $59 | $10.45 | +464.59% | 2 | Jan 30, 2023 | |
| CAH Cardinal Health | Maintains: Market Perform | $59 → $72 | $123.66 | -41.78% | 1 | Aug 16, 2022 | |
| OTRK Ontrak | Downgrades: Underperform | $3,150 → $810 | $1.68 | +48,114.29% | 2 | Aug 20, 2021 | |
| TDOC Teladoc Health | Maintains: Outperform | $240 → $188 | $10.16 | +1,750.39% | 1 | Aug 9, 2021 | |
| OSCR Oscar Health | Initiates: Market Perform | $29 | $16.60 | +74.70% | 1 | Mar 29, 2021 |
CVS Health
Nov 25, 2024
Maintains: Buy
Price Target: $73 → $80
Current: $56.48
Upside: +41.64%
Walgreens Boots Alliance
Oct 22, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $10.28
Upside: +36.19%
McKesson
May 8, 2024
Maintains: Buy
Price Target: $563 → $652
Current: $594.75
Upside: +9.63%
Chevron
Feb 24, 2023
Maintains: Outperform
Price Target: $185 → $170
Current: $149.19
Upside: +13.95%
Evolent Health
Jan 30, 2023
Maintains: Outperform
Price Target: $57 → $59
Current: $10.45
Upside: +464.59%
Cardinal Health
Aug 16, 2022
Maintains: Market Perform
Price Target: $59 → $72
Current: $123.66
Upside: -41.78%
Ontrak
Aug 20, 2021
Downgrades: Underperform
Price Target: $3,150 → $810
Current: $1.68
Upside: +48,114.29%
Teladoc Health
Aug 9, 2021
Maintains: Outperform
Price Target: $240 → $188
Current: $10.16
Upside: +1,750.39%
Oscar Health
Mar 29, 2021
Initiates: Market Perform
Price Target: $29
Current: $16.60
Upside: +74.70%